How many studies have been conducted on Rifaximin?

BiohacksAI has indexed 298 PubMed studies on Rifaximin, including 47 randomized controlled trials (RCTs). 75% of studies involve human subjects.

What are the main research areas for Rifaximin?

The primary research domains for Rifaximin are 🦠 Gut & Microbiome, 🫁 Liver & Detox, 🔬 Inflammation. This is based on analysis of 298 PubMed studies using the BiohacksAI evidence platform.

Rifaximin

A synthetic rifamycin derivative and anti-bacterial agent that is used for the treatment of GASTROENTERITIS caused by ESCHERICHIA COLI INFECTIONS. It may also be used in the treatment of HEPATIC ENCEPHALOPATHY.

298+ PubMed studies analyzed · 47 RCTs · Evidence Score: 57.4

Research Domains

Rifaximin has been studied across 16 research domains including 🦠 Gut & Microbiome, 🫁 Liver & Detox, 🔬 Inflammation, 🔬 Oncology, 🛡️ Immunity. The primary research focus is 🦠 Gut & Microbiome with 51% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Rifaximin, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Loading evidence profile...

This evidence profile for Rifaximin is generated deterministically from 298 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.